OMB APPROVAL
--------------------------
OMB Number: 3235-0059
Expires: July 31, 2004
Estimated average burden
hours per response...14.73
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement.
[ ] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14a-6(e)(2)).
[X] Definitive Proxy Statement.
[ ] Definitive Additional Materials.
[ ] Soliciting Material Pursuant to Section 240.14A-11(c) or Section 240.14a-12
KENSEY NASH CORPORATION
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
1) Title of each class of securities to which transaction applies:
- --------------------------------------------------------------------------------
2) Aggregate number of securities to which transaction applies:
- --------------------------------------------------------------------------------
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
- --------------------------------------------------------------------------------
4) Proposed maximum aggregate value of transaction:
- --------------------------------------------------------------------------------
5) Total fee paid:
- --------------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
- --------------------------------------------------------------------------------
2) Form, Schedule or Registration Statement No.:
- --------------------------------------------------------------------------------
3) Filing Party:
- --------------------------------------------------------------------------------
4) Date Filed:
- --------------------------------------------------------------------------------
PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS
FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB
CONTROL NUMBER.
SEC 1913 (11-01)
[KENSEY NASH CORPORATION LOGO]
Marsh Creek Corporate Center
55 East Uwchlan Avenue
Exton, Pennsylvania 19341
November 6, 2002
Dear Stockholder:
On behalf of the Board of Directors, I cordially invite you to attend the 2002
Annual Meeting of Stockholders of Kensey Nash Corporation. The Annual Meeting
will be held on Wednesday, December 4, 2002 beginning at 10:00 a.m., local time,
at the Top of the Tower, 1717 Arch Street, 51st Floor, Philadelphia, PA. The
formal notice of the Annual Meeting appears on the next page.
The attached Notice of Annual Meeting and Proxy Statement describe matters that
we expect will be acted upon at the meeting. At the meeting, we will present an
overview of the Company's business activities and recent performance and offer
the opportunity to ask questions.
It is important that your views be represented whether or not you are able to be
present at the Annual Meeting. Please sign and date the enclosed proxy card and
promptly return it to us in the postpaid envelope. If you sign and return your
proxy card without specifying your choices, it will be understood that you wish
to have your shares voted in accordance with the recommendations of the Board of
Directors contained in the Proxy Statement.
We are gratified by our stockholders' continued interest in Kensey Nash
Corporation and urge you to return your proxy card as soon as possible.
Sincerely,
Joseph W. Kaufmann
President and Chief Executive Officer
[KENSEY NASH CORPORATION LOGO]
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON DECEMBER 4, 2002
To the Stockholders of
Kensey Nash Corporation:
The Annual Meeting of Stockholders of Kensey Nash Corporation (the "Company")
will be held at 10:00 a.m., local time, on Wednesday, December 4, 2002, at the
Top of the Tower, 1717 Arch Street, 51st Floor, Philadelphia, PA for the
following purposes:
(1) To elect three Class I Directors to the Company's Board of Directors;
(2) To ratify the appointment by the Board of Directors of Deloitte &
Touche LLP as the independent auditors of the Company's financial
statements for the fiscal year ending June 30, 2003; and
(3) To transact such other business as may properly come before the
meeting or any adjournments or postponements thereof.
The Board of Directors has fixed the close of business on October 18, 2002 as
the record date for determining stockholders entitled to notice of, and to vote
at, the meeting.
By Order of the Board of Directors,
Joseph W. Kaufmann
President and Secretary
Exton, Pennsylvania
November 6, 2002
ALL STOCKHOLDERS ARE URGED TO ATTEND THE MEETING IN PERSON OR BY PROXY. WHETHER
OR NOT YOU EXPECT TO BE PRESENT AT THE MEETING, PLEASE COMPLETE, SIGN AND DATE
THE ENCLOSED PROXY CARD AND RETURN IT PROMPTLY IN THE ENCLOSED POSTAGE PAID
ENVELOPE FURNISHED FOR THAT PURPOSE.
KENSEY NASH CORPORATION
MARSH CREEK CORPORATE CENTER
55 EAST UWCHLAN AVENUE
EXTON, PENNSYLVANIA 19341
(610) 524-0188
PROXY STATEMENT
THE ACCOMPANYING PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF KENSEY NASH
CORPORATION, A DELAWARE CORPORATION, FOR USE AT ITS ANNUAL MEETING OF
STOCKHOLDERS (THE "ANNUAL MEETING") TO BE HELD AT 10:00 A.M., LOCAL TIME,
WEDNESDAY, DECEMBER 4, 2002, AT THE TOP OF THE TOWER, 1717 ARCH STREET, 51ST
FLOOR, PHILADELPHIA, PENNSYLVANIA, AND ANY ADJOURNMENTS OR POSTPONEMENTS
THEREOF. THIS PROXY STATEMENT AND ACCOMPANYING FORM OF PROXY ARE BEING MAILED TO
STOCKHOLDERS ON OR ABOUT NOVEMBER 6, 2002.
VOTING SECURITIES -- The Board of Directors has fixed the close of business on
October 18, 2002, as the record date (the "Record Date") for the determination
of stockholders entitled to notice of, and to vote at, the Annual Meeting or any
adjournments or postponements thereof. As of the Record Date, the Company had
outstanding 10,753,734 shares of its Common Stock. Each of the outstanding
shares of Common Stock is entitled to one vote on all matters to come before the
Annual Meeting.
PROXIES -- Joseph W. Kaufmann and Douglas G. Evans, the persons named as proxies
on the proxy card accompanying this Proxy Statement, were selected by the Board
of Directors of the Company to serve in such capacity. Messrs. Kaufmann and
Evans are officers and directors of the Company. Each executed and returned
proxy will be voted in accordance with the directions indicated thereon, or if
no direction is indicated, such proxy will be voted in accordance with the
recommendations of the Board of Directors contained in this Proxy Statement.
Each stockholder giving a proxy has the power to revoke it at any time before
the shares it represents are voted. Revocation of a proxy is effective upon
receipt by the Secretary of the Company of either (1) an instrument revoking the
proxy, or (2) a duly executed proxy bearing a later date. Additionally, a
stockholder may change or revoke a previously executed proxy by voting in person
at the Annual Meeting, but attendance at the Annual Meeting will not by itself
revoke a proxy.
QUORUM - The required quorum for the transaction of business at the Annual
Meeting will be a majority of the outstanding shares of Common Stock entitled to
vote on the Record Date. Broker non-votes are included for purposes of
determining whether a quorum is present at the Annual Meeting. A broker non-vote
occurs when a nominee holding shares for a beneficial owner does not vote on a
particular proposal because the nominee does not have discretionary voting power
with respect to that item and has not received instructions from the beneficial
owner.
REQUIRED VOTE -- A plurality of the votes of shares present in person or
represented by proxy at the Annual Meeting is required to elect the nominees for
director. This means that the three nominees receiving the highest number of
"FOR" votes will be elected. Stockholders will not be allowed to cumulate their
votes in the election of directors. Broker non-votes will have no effect in the
election of directors. A majority of the votes of shares present in person or
represented by proxy is required to ratify the appointment of Deloitte & Touche
LLP as the independent auditors of the Company's financial statements for the
fiscal year ending June 30, 2003. Abstentions will have the same effect as votes
against this proposal. Broker non-votes will have no effect on the voting on
this proposal.
STOCKHOLDER LIST -- A list of stockholders entitled to vote at the Annual
Meeting, arranged in alphabetical order, showing the address of and number of
shares registered in the name of each stockholder, will be open to the
examination of any stockholder for any purpose germane to the Annual Meeting
during ordinary business hours commencing November 22, 2002, and continuing
through the date of the Annual Meeting at the offices of the Company, 55 East
Uwchlan Avenue, Exton, Pennsylvania 19341.
ANNUAL REPORT TO STOCKHOLDERS -- THE COMPANY'S ANNUAL REPORT TO STOCKHOLDERS FOR
THE FISCAL YEAR ENDED JUNE 30, 2002 ("FISCAL YEAR 2002"), CONTAINING FINANCIAL
AND OTHER INFORMATION PERTAINING TO THE COMPANY, IS BEING FURNISHED TO
STOCKHOLDERS SIMULTANEOUSLY WITH THIS PROXY STATEMENT.
PROPOSAL 1
ELECTION OF DIRECTORS
Before the resignation of Kenneth R. Kensey, M.D. on October 30, 2001, the
Company's Board of Directors consisted of nine directors. The Board of Directors
will consist of eight directors unless and until the vacancy created by Dr.
Kensey's resignation is filled. Article Five of the Company's Certificate of
Incorporation, as amended, provides that the Board of Directors shall be
classified with respect to the terms for which its members shall hold office by
dividing the members into three classes. At the Annual Meeting, three Class I
Directors are to be elected for a term of three years expiring at the 2005
Annual Meeting of Stockholders. THE BOARD OF DIRECTORS RECOMMENDS THAT THE
STOCKHOLDERS VOTE IN FAVOR OF THE ELECTION OF THE NOMINEES NAMED IN THIS PROXY
STATEMENT TO CONTINUE TO SERVE AS DIRECTORS OF THE COMPANY. See "Nominees"
below.
The five directors whose terms of office expire in 2003 and 2004 will continue
to serve after the Annual Meeting until such time as their respective terms of
office expire or their successors are duly elected and qualified. See "Other
Directors" below.
If at the time of the Annual Meeting any of the nominees should be unable or
decline to serve, the person named in the proxy will vote for such substitute
nominee or nominees as the Board of Directors recommends, or vote to allow the
vacancy created thereby to remain open until filled by the Board of Directors,
as the Board of Directors recommends. The Board of Directors has no reason to
believe that any nominee will be unable or will decline to serve as a director
if elected.
NOMINEES
The names of the nominees for the office of director, together with certain
information concerning such nominees, are set forth below:
SERVED AS
NAME AGE POSITION WITH COMPANY DIRECTOR SINCE
------------------------------- --- ------------------------ --------------
Douglas G. Evans, P.E. ........ 38 Chief Operating Officer, 1995
Assistant Secretary and
Director
Walter Maupay.................. 63 Director 1995
C. McCollister Evarts, M.D. ... 71 Director 2000
Mr. Evans has served as Chief Operating Officer and as Assistant Secretary of
the Company since 1995 and was also elected as a Director in 1995. Mr. Evans is
responsible for protecting and developing the Company's intellectual property,
assessing new technologies, and overseeing the Company's daily operations. From
1989 to 1993, Mr. Evans held several senior positions with the Company in
product development and engineering. From 1986 until joining the Company in
1989, Mr. Evans held a number of positions in engineering and business
development for several divisions of the General Electric Company. Mr. Evans
received a B.S. degree in Engineering Science and a Masters degree in Business
Management from The Pennsylvania State University and an M.S. degree in
Electrical Engineering from the University of Pennsylvania. Mr. Evans is a
Registered Professional Engineer in the United States.
Mr. Maupay has been a Director of the Company since 1995. In 1995, prior to his
retirement, Mr. Maupay was a group executive with Bristol-Myers Squibb, which
acquired Calgon Vestal Laboratories at the end of 1994. From 1988 until 1994,
Mr. Maupay served as President of Calgon Vestal Laboratories, then a division of
Merck & Co. Mr. Maupay spent thirty-three years in corporate and divisional
positions at Merck & Co. Mr. Maupay received a
2
B.S. degree in Pharmacy from Temple University and an M.B.A. degree from Lehigh
University. Mr. Maupay has been a director of Life Medical Sciences, Inc. and
Cubist Pharmaceuticals and is a director of PolyMedica Corporation as well as
several private companies. Mr. Maupay is a member of the Company's Compensation,
Audit, Executive, Corporate Governance and Nominating Committees.
Dr. Evarts has been a Director of the Company since July 2000. Dr. Evarts is a
University Professor for The Pennsylvania State University, Chief Executive
Officer of The Milton S. Hershey Medical Center, Senior Vice President for
Health Affairs and Dean (Emeritus) for The Pennsylvania State University's
College of Medicine. Previously, Dr. Evarts served as Professor and Chair of the
Department of Orthopedics at the University of Rochester School of Medicine and
Dentistry and Medical Center Vice President for Development. Prior to that, he
was Chair of the Department of Orthopedic Surgery at the Cleveland Clinic
Foundation. Dr. Evarts holds an A.B. degree from Colgate University. He
graduated with an M.D. from the University of Rochester School of Medicine and
Dentistry and served his internship and residency at the University of Rochester
Strong Memorial Hospital. Dr. Evarts is Chairman of the Company's Audit
Committee and a member of the Executive, Corporate Governance and Nominating
Committees.
OTHER DIRECTORS
The following persons will continue to serve as Directors of the Company after
the Annual Meeting until their terms of office expire (as indicated below) or
until their successors are elected and qualified.
SERVED AS TERM
NAME AGE POSITION WITH COMPANY DIRECTOR SINCE EXPIRES
- ------------------------------- --- ------------------------------------ -------------- -------
Joseph W. Kaufmann........... 50 Chief Executive Officer, President, 1992 2003
Secretary and Director
Harold N. Chefitz ........... 67 Director 1995 2003
Steven J. Lee ............... 55 Director 2000 2003
John E. Nash, P.E. .......... 67 Vice President of New Technology and 1984 2004
Director
Robert J. Bobb............... 55 Director 1984 2004
Mr. Kaufmann has served as Chief Executive Officer and President of the Company
since 1995, as Secretary since 1989, and as a Director since 1992. Mr. Kaufmann
joined the Company in 1989 as Chief Financial Officer and was appointed Vice
President, Finance and Administration in January 1994. Prior to joining the
Company, Mr. Kaufmann held executive finance positions at divisions of both
Hanson, PLC and Syntex Corporation. Mr. Kaufmann received a B.S. degree in
Accounting from St. Joseph's University. Mr. Kaufmann is Chairman of the
Company's Executive Committee.
Mr. Chefitz has been a Director of the Company since June 1995. Mr. Chefitz has
numerous years of experience in investment banking in the healthcare industry
and is presently a General Partner at CK Capital L.P., a Partner at Boles Knop &
Company LLC, and Chairman of the Board and Chief Executive Officer of GliaMed,
Inc. and is a director of Barr Laboratories. He was a Senior Managing Director
of Gerard Klauer Mattison & Co. LLC from June 1995 through November 1998. From
March 1993 until March 1995, he served as a Managing Director and Head of
Healthcare Investment Banking for Prudential Securities Incorporated in New York
City. Mr. Chefitz received a B.S. degree from Boston University and attended
Boston College Law School. Mr. Chefitz is a member of the Company's
Compensation, Executive, Corporate Governance and Nominating Committees.
Mr. Lee has been a Director of the Company since July 2000. Mr. Lee was a
founder and served as Chairman and Chief Executive Officer of PolyMedica
Corporation from July 1996 through July 2002. Prior to becoming Chief
3
Executive Officer, Mr. Lee served as President and a director of PolyMedica from
1990 through June 1996. Previously, he was President and a director of Shawmut
National Ventures from 1987 to 1990 and served as President, Chief Executive
Officer and a director of RepliGen Corporation from 1984 to 1986. Mr. Lee
received a B.A. from Lehigh University cum laude, an M.B.A. from the Wharton
School of Finance and Commerce at the University of Pennsylvania, and a J.D.
degree from Fordham University School of Law. Mr. Lee is a director of
PolyMedica Corporation, ICN Pharmaceuticals Inc. and Fibersense Technology
Corporation. Mr. Lee is a member of the Company's Audit Committee.
Mr. Nash is a co-founder of the Company, is currently the Vice President of New
Technologies and has served as a Director since 1984. He served as Vice Chairman
of the Board and Executive Vice President from 1984 to October 1998. Prior to
his co-founding the Company, Mr. Nash was employed by Syntex Corporation in a
number of engineering and development positions within its Syntex Dental
subsidiary, including Vice President of Research and Development. Mr. Nash holds
qualifications in Mechanical and Production Engineering from Kingston College of
Technology in the United Kingdom and is a Registered Professional Engineer in
both the United Kingdom and the United States.
Mr. Bobb has been a Director of the Company since 1984. For over fifteen years,
Mr. Bobb has been a principal equity investor and key management participant in
a number of operating companies. Mr. Bobb received a B.S. degree from Western
Michigan University and a J.D. degree from the University of Notre Dame Law
School and studied at the University of Belgrade and the University of London.
Mr. Bobb is Chairman of the Company's Compensation Committee and a member of the
Company's Audit Committee.
DIRECTOR COMPENSATION -- The Company does not pay additional cash compensation
to executive officers for their service as directors. During fiscal year 2002,
non-employee directors were paid a fee of $2,500 per meeting (not to exceed
$10,000 per fiscal year) plus travel expenses and other costs associated with
attending meetings. In addition, non-employee directors who served on the
Executive Committee were paid a fee of $1,500 per Executive Committee meeting
plus travel expenses and other costs associated with attending the meetings.
Pursuant to the Kensey Nash Corporation Nonemployee Directors' Stock Option Plan
(the "Directors' Plan"), each of Messrs. Bobb, Chefitz and Maupay was granted
options to purchase 5,000 shares of Common Stock upon the Company's initial
public offering, exercisable at $12.00 per share. Each of Mr. Lee and Dr. Evarts
was granted options to purchase 5,000 shares of Common Stock upon their initial
appointment to the Board of Directors, exercisable at $10.75 per share, the fair
market value on the date of grant. In consideration of their service on the
Board of Directors, on the date of each annual meeting of the stockholders of
the Company, each non-employee director who is elected, re-elected or continues
to serve as a director because his term has not expired, receives an option to
purchase 7,500 shares of Common Stock, exercisable at the fair market value of
such shares on the date of grant. In addition, each Director who serves on a
Committee, as of the date of the annual meeting, receives an additional option
to purchase 2,500 shares of Common Stock, exercisable at the fair market value
of such shares on the date of grant. Each Committee member is only entitled to a
single such option to purchase 2,500 shares even if he serves on several
Committees. In addition, the Directors' Plan provides that additional grants of
options may be made, from time-to-time, as determined by the Compensation
Committee.
MEETINGS -- During fiscal year 2002, the Board of Directors held six formal
meetings including teleconference meetings. Each director attended at least 75%
of the aggregate of (1) the total number of meetings of the Board of Directors
held during the period for which he served as a director except for Mr. Lee who
missed two of the six meetings held in fiscal year 2002, and (2) the total
number of meetings held by all committees of the Board of Directors on which he
served.
COMMITTEES OF THE BOARD OF DIRECTORS-- The Board of Directors has established an
Audit Committee, a Compensation Committee and an Executive Committee. The Audit
Committee includes Dr. Evarts (Chairman) and Messrs. Maupay, Bobb and Lee, each
a non-employee director and each of whom meets the independence requirements of
the NASDAQ Marketplace Rules. The Compensation Committee includes Messrs. Bobb
4
(Chairman), Chefitz and Maupay. The Executive Committee includes Messrs.
Kaufmann (Chairman), Chefitz, Maupay and Dr. Evarts.
In September 2002, the Executive Committee established a Corporate Governance
Committee and a Nominating Committee. Messrs. Maupay and Chefitz and Dr. Evarts,
each an independent director, will serve on both of these committees. The
primary function of the Governance Committee will be to evaluate the Board's
performance and make recommendations as to the size and composition of the Board
and its committees. The Nominating Committee will be responsible for making
recommendations to the Board for nominations of new Board members.
The Audit Committee generally has responsibility for assessing processes related
to risks and control environment, overseeing financial reporting, evaluating
independent audit processes and reporting to the full Board of Directors
regarding all of the foregoing. The Audit Committee held three formal meetings
in fiscal year 2002. See "Audit Committee Matters."
The Compensation Committee generally has responsibility for recommending to the
Board of Directors guidelines and standards for the determination of executive
compensation, reviewing the Company's executive policies and reporting to the
full Board of Directors regarding the foregoing. The Compensation Committee also
has responsibility for administering the Company's Third Amended and Restated
Employee Incentive Compensation Plan (the "Employee Plan") and the Directors'
Plan, determining the number of options to be granted to the Company's executive
officers and employees pursuant to the Employee Plan, and reporting to the full
Board of Directors regarding the foregoing matters. The Compensation Committee
did not hold any formal meetings in fiscal year 2002. However, the Compensation
Committee met on July 10, 2002 to discuss compensation awards for the
performance in fiscal year 2002. See "Report of the Compensation Committee of
the Board of Directors."
The Executive Committee has those responsibilities delegated to it from time to
time by the Board of Directors. The Executive Committee also measures the
Company's performance to the Company's operating plan and reviews key strategic
options. The Executive Committee held four formal meetings in fiscal year 2002.
EXECUTIVE OFFICERS
The Board of Directors elects officers annually and such officers, subject to
the terms of certain employment agreements, serve at the discretion of the
Board. See "Executive Compensation -- Employment Agreements." In addition to the
executive officers identified in the tables entitled "Nominees" and "Other
Directors", Ms. Wendy F. DiCicco, serves as the Company's Chief Financial
Officer.
Ms. DiCicco, CPA, 35, has served as Chief Financial Officer since August 1998.
From 1996 through 1998, Ms. DiCicco served as Controller. Prior to joining the
Company in 1996, Ms. DiCicco was an Accounting and Audit Manager at the public
accounting firm Deloitte & Touche LLP, where she was employed since 1989. Ms.
DiCicco holds a B.S. degree in accounting from Philadelphia University and is a
Certified Public Accountant in the Commonwealth of Pennsylvania.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE -- Section 16 of the
Securities and Exchange Act of 1934, as amended (the "1934 Act"), requires the
Company's officers and directors and persons who own greater than 10% of a
registered class of the Company's equity securities to file reports of ownership
and changes in ownership with the Securities and Exchange Commission (the "SEC")
and the NASDAQ National Market. Based solely on a review of the forms it has
received and on written representations from certain reporting persons that no
such forms were required for them, the Company believes that all Section 16
filing requirements applicable to its officers, directors and 10% beneficial
owners were complied with during fiscal year 2002, except that Mr. Nash and Dr.
Kensey each inadvertently filed one Form 4 to report five and ten transactions,
respectively, four days late due to an administrative error.
5
EXECUTIVE COMPENSATION
The table below contains information with respect to the compensation paid and
awarded by the Company for services rendered during the fiscal years ended June
30, 2002, 2001, and 2000 to its chief executive officer and the only three other
executive officers of the Company whose total annual salary and bonus exceeded
$100,000 during fiscal year 2002 (each, a "Named Executive Officer").
SUMMARY COMPENSATION TABLE
ANNUAL LONG-TERM
COMPENSATION COMPENSATION ALL OTHER
(1) AWARDS COMPENSATION
------------ ------------------ ------------
SECURITIES
SALARY UNDERLYING OPTIONS
NAME AND PRINCIPAL POSITION YEAR ($) (#)
------------------------------------ ---- ------------ ------------------ ------------
Joseph W. Kaufmann 2002 $ 250,000 55,000(4) --
President, Chief Executive Officer, 2001 $ 237,500 168,500 --
Secretary and Director 2000 $ 200,000 75,000(5) --
Douglas G. Evans, P.E. 2002 $ 200,000 45,000(4) $ 2,250(6)
Chief Operating Officer, Assistant 2001 $ 190,000 133,200 $ 1,750(6)
Secretary and Director 2000 $ 160,000 75,000(5) $ 211(6)
Wendy F. DiCicco, CPA 2002 $ 127,282 15,000(4) $ 1,896(6)
Chief Financial Officer 2001 $ 114,670(2) 15,525 $ 1,557(6)
2000 $ 98,067 20,000(5) $ 950(6)
John E. Nash, P.E. 2002 $ 100,000 -- $ 1,292(6)
Vice President of New Technologies 2001 $ 97,280(3) -- $ 1,039(6)
2000 $ 180,000 -- $ 1,460(6)
- ----------
(1) Each of Mr. Kaufmann and Mr. Evans elected not to receive a bonus for
fiscal year 2000 and 2002 under the Company's bonus plan and each of Mr.
Kaufmann, Mr. Evans, and Ms. DiCicco elected to receive options to purchase
98,500, 80,000, and 8,625 shares of the Company's Common Stock,
respectively, in lieu of a cash bonus for fiscal year 2001 under the
Company's bonus plan.
(2) The Company's short-term disability insurance carrier paid $9,390 of Ms.
DiCicco's salary.
(3) The Company's short-term disability insurance carrier paid $19,176 of Mr.
Nash's salary.
(4) Granted July 10, 2002.
(5) Granted August 16, 2000.
(6) Represents the Company's matching cash contribution paid and/or accrued
under the Company's 401(k) Plan.
6
OPTION GRANTS IN FISCAL YEAR 2002 -- The following table provides information on
grants of stock options for fiscal year 2002 to the Named Executive Officers
pursuant to the Employee Plan. These grants were made on July 10, 2002. The
Company did not award any stock appreciation rights during fiscal year 2002. .
OPTION GRANTS IN FISCAL YEAR 2002
INDIVIDUAL GRANTS
- ------------------------------------------------------------------------------------
POTENTIAL REALIZABLE VALUE AT
PERCENT OF ASSUMED ANNUAL RATES OF
TOTAL STOCK PRICE APPRECIATION FOR
OPTIONS OPTION TERM(2)
OPTIONS GRANTED TO EXERCISE -----------------------------
GRANTED EMPLOYEES IN PRICE EXPIRATION
NAME (#)(1) FISCAL YEAR ($/SH) DATE 5%($) 10%($)
- ------------------------------ ------- ------------ -------- ---------- ------------ ------------
Joseph W. Kaufmann ........... 55,000 14.1% $ 14.58 7/10/12 $ 504,311 $1,278,022
Douglas G. Evans, P.E. ....... 45,000 11.6% $ 14.58 7/10/12 $ 412,618 $1,045,654
Wendy F. DiCicco, CPA ........ 15,000 3.9% $ 14.58 7/10/12 $ 137,539 $ 348,551
John E. Nash, P.E. ........... -- -- -- -- -- --
(1) These options will vest in equal annual amounts beginning on July 1,
2003.
(2) Potential realizable value is presented net of the option exercise
price but before any federal or state income taxes associated with
exercise. These amounts represent certain assumed rates of
appreciation prescribed by the SEC. Actual gains are dependent on the
future performance of the common stock and the option holders'
continued employment over the vesting period. The potential realizable
value does not reflect the Company's prediction of its stock price
performance. The amounts reflected in the table may not be achieved.
AGGREGATED OPTION EXERCISES IN FISCAL YEAR 2002 AND YEAR-END 2002 OPTION VALUES
- -- The following table provides information on the Named Executive Officers'
unexercised and exercised options granted under the Employee Plan at June 30,
2002. It does not reflect the grants made to the Named Executive Officers on
July 10, 2002.
AGGREGATED OPTION EXERCISES IN FISCAL YEAR 2002 AND YEAR-END 2002 OPTION VALUES
NUMBER OF SECURITIES VALUE OF UNEXERCISED
SHARES UNDERLYING UNEXERCISED IN-THE-MONEY OPTIONS AT
ACQUIRED ON VALUE OPTIONS AT YEAR-END 2002(#) YEAR-END 2002($)(1)
EXERCISE REALIZED ---------------------------- ----------------------------
NAME (#) ($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- -------------------------- ----------- -------- ----------- ------------- ----------- -------------
Joseph W. Kaufmann ....... -- -- 894,500 80,000 $5,398,222 $ 181,368
Douglas G. Evans, P.E. ... -- -- 554,400 68,800 $3,225,668 $ 162,440
Wendy F. DiCicco, CPA .... 10,000 $ 125,823 58,925 14,600 $ 287,938 $ 38,524
John E. Nash, P.E. ....... -- -- -- -- -- --
- ----------
(1) The value per option is calculated by subtracting the exercise price
from the closing price of the Common Stock on the NASDAQ National
Market on June 28, 2002 of $16.20.
EMPLOYMENT AGREEMENTS
Mr. Kaufmann is a party to a three year Employment and Non-Competition Agreement
dated as of July 1, 2001 that expires in July 2004 and provides for an annual
base salary of $250,000. Mr. Evans is a party to a three year Employment and
Non-Competition Agreement dated as of July 1, 2001 that expires in July 2004 and
provides for an annual base salary of $200,000. Ms. DiCicco is a party to a two
year Employment and Non-Competition Agreement dated as of September 1, 2001 that
expires in September 2003 and provides for an annual base salary of $119,503.
Each of these employment agreements provides that the officer's salary is
subject to annual increases as determined by the Board of Directors and provides
that an annual bonus may be paid at the discretion
7
of the Board of Directors. The agreements restrict each of Messrs. Kaufmann and
Evans and Ms. DiCicco from competing with the Company during the term of the
agreement and for 12 months after termination of his or her employment with the
Company.
Each of Messrs. Kaufmann and Evans and Ms. DiCicco is also party to a
Termination and Change in Control Agreement, dated as of the same date as his or
her Employment and Non-Competition Agreement, pursuant to which, upon a Change
in Control or Termination (each as defined therein) he or she will be entitled
to receive, among other things, severance pay equal to his or her base salary
for a period of two years. Each of Messrs. Kaufmann and Evans and Ms. DiCicco
would be entitled to receive an additional payment, net of taxes, to compensate
for any excise tax imposed on these and other payments if they are determined to
be excess parachute payments under the Internal Revenue Code. Following a Change
in Control, all unvested options granted to each of Messrs. Kaufmann and Evans
and Ms. DiCicco will immediately become vested.
EQUITY COMPENSATION PLAN INFORMATION
The following table provides information about the securities authorized for
issuance under the Company's equity compensation plans, all of which have been
approved by stockholders, as of June 30, 2002.
NUMBER OF SECURITIES
REMAINING AVAILABLE FOR
NUMBER OF SECURITIES FUTURE ISSUANCE UNDER
TO BE ISSUED UPON WEIGHTED-AVERAGE EXERCISE EQUITY COMPENSATION
EXERCISE OF PRICE OF OUTSTANDING PLANS (EXCLUDING
OUTSTANDING OPTIONS, OPTIONS, WARRANTS SECURITIES REFLECTED IN
WARRANTS AND RIGHTS AND RIGHTS COLUMN (a)
-------------------- ------------------------- -----------------------
(a) (b) (c)
-------------------- ------------------------- -----------------------
Equity compensation plans approved by
security holders 2,477,440 $ 11.45 699,268
Equity compensation plans not approved
by security holders -- $ -- --
REPORT OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
The objectives of the Compensation Committee in determining the levels and
components of executive compensation are (1) retaining the executive officers in
their present positions, (2) providing them with both cash and equity incentives
to further the interests of the Company and its stockholders, (3) compensating
them at levels comparable to those of executive officers at other medical device
companies at a comparable stage of development, and (4) attracting executive
officers whose experience and backgrounds would help the growth and development
of the Company. Generally, the compensation of all executive officers consists
of a base salary plus a discretionary bonus based upon achievement of specified
goals. In addition, stock options are granted to provide the opportunity for
compensation based upon the performance of the Common Stock over time.
The Compensation Committee determined the terms of the employment agreements for
Mr. Kaufmann and for all of the other executive officers. In determining the
base salaries of the executive officers, the Compensation Committee considered
the performance of each executive, the nature of the executive's
responsibilities, the salary levels of executives at medical device companies at
a comparable stage of development, including other publicly-held companies that
are developing medical device products and are included in the NASDAQ Medical
Equipment Index, and the Company's general compensation practices. Based on
these criteria, the employment agreement for Mr. Kaufmann provides for a base
salary of $250,000 for fiscal years 2002, 2003 and 2004.
8
Discretionary bonuses for each of the Company's executive officers are directly
tied to achievement of specified goals of the Company and are a function of the
criteria, which the Compensation Committee believes appropriately, take into
account the specific areas of responsibility of the particular officer. The
Compensation Committee approved specific goals, including financial, operational
and development milestones, in the beginning of fiscal year 2002. Based upon
achievement of the approved goals for fiscal year 2002, Mr. Kaufmann and Mr.
Evans earned a cash bonus of $101,000 and $87,000, respectively. However, each
of Mr. Kaufmann and Mr. Evans elected not to receive a cash bonus for fiscal
year 2002 under the Company's bonus plan. Mr. Kaufmann's bonus for fiscal year
2003 will be based upon the achievement of specified objectives, including
achievement of revenue and earnings per share goals in the Company's fiscal year
2003 plan. The fiscal year 2003 bonus will be subject to the discretion of the
Board of Directors.
The Compensation Committee also grants stock options, from time to time, to
executive officers and other employees in order to provide a long-term incentive
which is directly tied to the performance of the Company's stock. The exercise
price of each of these stock options is generally the fair market value of the
Common Stock on the date of grant. The options generally vest over a three-year
period, based on either the date of grant or July 1st of each fiscal year.
Vesting periods are used to retain key employees and to emphasize the long-term
aspect of contribution and performance. On July 10, 2002, the Compensation
Committee approved a grant of options to purchase 55,000 shares of the Company's
Common Stock to Mr. Kaufmann, options to purchase 45,000 shares to Mr. Evans,
and options to purchase 15,000 shares to Ms. DiCicco. These option grants will
vest in equal amounts over a three-year period and the exercise price is $14.58,
the fair market value of the underlying Common Stock on the date of the grant.
The Compensation Committee granted options based upon its belief that it is
necessary in a highly competitive environment to provide key personnel the
opportunity for significant continuing equity participation and incentive to
create stockholder value over a longer investment horizon. These options provide
an incentive to maximize stockholder value because they reward option holders
only if stockholders also benefit. In making stock option grants to executives
under the Employee Plan, the Compensation Committee considered a number of
factors, including the past performance of the executive, achievement of
specific delineated goals, the responsibilities of the executive, review of
compensation of executives in medical device companies at a comparable stage of
development, and review of the number of shares underlying stock options each
executive currently possesses.
COMPLIANCE WITH SECTION 162(m) -- The Compensation Committee currently intends
for all compensation paid to the executive officers to be tax deductible to the
Company. Section 162(m) of the Internal Revenue Code ("Section 162(m)"),
provides that compensation paid to certain executive officers in excess of
$1,000,000 is nondeductible by the Company for Federal income tax purposes
unless, in general, such compensation is performance-based, is established by a
committee comprised solely of two or more independent directors, is objective
and the plan or agreement providing for such performance based compensation has
been approved by stockholders in advance of payment. The Compensation Committee
does not believe that the limitation imposed by Section 162(m) will be
applicable to the Company in the foreseeable future, but the Company will review
compensation practices as circumstances warrant.
COMPENSATION COMMITTEE
--------------------------
Robert J. Bobb, Chairman
Harold N. Chefitz
Walter R. Maupay, Jr.
9
PERFORMANCE GRAPH
The following graph shows a comparison of cumulative total returns during the
period commencing on June 30, 1997 and ending on June 30, 2002, for the Company,
the NASDAQ Stock Market (U.S.) Index, the Russell 2000 Index and the NASDAQ
Medical Equipment Index. This year, the Company has decided to replace the
Russell 2000 Index with the NASDAQ Medical Equipment Index in its performance
graph, as the Company believes that the NASDAQ Medical Equipment Index includes
companies that are more comparable to the Company, and provides a better basis
for assessing the Company's stock performance than the Russell 2000 Index.
Pursuant to SEC rules, both indices are included in this performance graph, but
beginning with the Company's proxy statement for its 2003 Annual Meeting of
Stockholders, the Russell 2000 Index will no longer be included. The comparison
assumes $100 was invested on June 30, 1997, in the Common Stock of the Company,
the NASDAQ Stock Market (U.S.) Index, the Russell 2000 Index, and the NASDAQ
Medical Equipment Index, and assumes the reinvestment of all dividends, if any.
COMPARISON OF CUMULATIVE TOTAL RETURNS
[PERFORMANCE GRAPH]
6/30/97 6/30/98 6/30/99 6/30/00 6/30/01 6/30/02
------- ------- ------- ------- ------- -------
KENSEY NASH CORPORATION 100 88 74 103 156 151
NASDAQ Stock Market (U.S.) 100 132 189 280 152 103
Russell 2000 Index 100 117 118 135 136 124
NASDAQ Medical Equipment 100 116 155 179 168 152
10
SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN STOCKHOLDERS
The following table sets forth, as of October 18, 2002, certain information with
respect to the beneficial ownership of the Company's Common Stock by (1) each
person known by the Company to own beneficially more than 5% of the outstanding
shares of Common Stock, (2) each Company director, (3) each of the Named
Executive Officers and (4) all Company executive officers and directors as a
group. Unless otherwise indicated, each person or group has sole investment and
voting power with respect to the shares shown below as beneficially owned by
such person.
AMOUNT AND NATURE OF PERCENT OF
NAMES AND ADDRESS BENEFICIAL OWNERSHIP CLASS
---------------------------------------------------- -------------------- ----------
FMR Corp.(1) ...................................... 1,230,800 11.5%
Taunus Corporation(2) ............................. 1,170,031 10.9
Kenneth R. Kensey, M.D.(3)(4) ..................... 1,110,000 10.3
Joseph W. Kaufmann(5) ............................. 1,077,000 9.2
Douglas G. Evans, P.E.(6) ......................... 680,117 6.0
John E. Nash, P.E.(7) ............................. 535,000 5.0
Wendy F. DiCicco, CPA(8) .......................... 63,925 *
Walter R. Maupay, Jr.(9) .......................... 75,500 *
Harold N. Chefitz(10) ............................. 52,500 *
Robert J. Bobb(11) ................................ 52,500 *
Steven J. Lee(12) ................................. 15,834 *
C. McCollister Evarts, M.D.(13) ................... 15,834 *
All Executive Officers and Directors as a group
(9 persons)..................................... 2,568,210 20.6%
- ----------
* Denotes less than one percent.
(1) FMR Corp. is a parent holding company of Fidelity Management & Research
Company whose address is 82 Devonshire Street, Boston, MA 02109. Includes
813,900 shares as to which FMR Corp. does not have sole or shared voting
power. This information was obtained from a Schedule 13G filed with the SEC
on February 14, 2002.
(2) Taunus Corporation is a parent holding company of Deutsche Investment
Management Americas Inc. (DIMA). The principal place of business for Taunus
is 31 West 52nd Street, NY, NY 10019 and the principal place of business
for DIMA is 345 Park Avenue, NY, NY 10154. Includes 20,624 shares as to
which Taunus Corporation shares voting power and 442,400 shares as to which
Taunus does not have sole or shared voting power. This information was
obtained from a Schedule 13G filed with the SEC on May 3, 2002.
(3) The address of the stockholder is c/o Visco Technologies, Inc., 15 East
Uwchlan Ave., Suite 414, Exton, Pennsylvania 19341.
(4) Represents shares held by the Kenneth Kensey Revocable Trust. Excludes
18,750 shares held by the Kenneth Kensey Gift Trust, as to which Dr. Kensey
disclaims beneficial interest. With respect to 400,000 of the shares held
by the Kenneth Kensey Revocable Trust, Dr. Kensey has entered into "zero
cost collars" pursuant to which Dr. Kensey wrote call options to, and
purchased put options from, Bear, Stearns & Co. Inc.
(5) Includes options to purchase 911,167 shares which may be exercised within
60 days as of October 18, 2002.
(6) Represents 54,000 shares held by the Douglas G. Evans Revocable Trust,
1,050 shares held indirectly by his minor children and options to purchase
571,067 shares which may be exercised within 60 days of October 18, 2002.
(7) Represents shares held by the John E. Nash Revocable Trust.
(8) Includes options to purchase 63,925 shares held by Ms. DiCicco which may be
exercised within 60 days of October 18, 2002.
(9) Includes options to purchase 52,500 shares which may be exercised within 60
days of October 18, 2002.
(10) Represents 5,000 shares held by the Chefitz Healthcare Investment Account
and options to purchase 47,500 shares of Common Stock held by Mr. Chefitz
which may be exercised within 60 days of October 18, 2002.
(11) Includes options to purchase 52,500 shares held by Mr. Bobb which may be
exercised within 60 days of October 18, 2002.
(12) Includes options to purchase 15,834 shares held by Mr. Lee which may be
exercised within 60 days of October 18, 2002.
(13) Includes options to purchase 15,834 shares held by Dr. Evarts which may be
exercised within 60 days of October 18, 2002.
11
CERTAIN TRANSACTIONS
The Company has pledged $1,726,780 in investments as collateral to secure a bank
loan made to Joseph W. Kaufmann, the Company's Chief Executive Officer,
President and Secretary, who is also a Director, which were used by Mr. Kaufmann
for the payment of taxes incurred as a result of the receipt of Common Stock at
the Company's initial public offering in December 1995. In exchange for the
Company pledging collateral for such loans, Mr. Kaufmann has pledged his Common
Stock as collateral to the Company. The loan is repayable at the earlier of the
sales of his stock or December 2002. The balance outstanding was $1,695,983 at
June 30, 2002.
The Company has pledged $386,291 in investments as collateral to secure a bank
loan made to Douglas G. Evans, P.E., the Company's Chief Operating Officer, and
Assistant Secretary, who is also a Director, which were used by Mr. Evans for
the payment of taxes incurred as a result of the receipt of Common Stock at the
Company's initial public offering in December 1995. In exchange for the Company
pledging collateral for such loans, Mr. Evans has pledged his Common Stock as
collateral to the Company. The loan is repayable at the earlier of the sales of
his stock or December 2002. The balance outstanding was $379,359 at June 30,
2002.
The Company entered into loan agreements with Joseph W. Kaufmann under which he
has borrowed $1.8 million in total from the Company since May 1997. Interest on
the loans range from 5.75% to 7.75% and is based on the prime rate of interest.
In exchange for the loans, Mr. Kaufmann has pledged his common stock as
collateral to the Company. Interest and principal on the loans are due at the
earlier of the sale of a portion of the officer's stock or March 2003. The full
principal amount of the loan remained outstanding at June 30, 2002.
PROPOSAL 2
RATIFICATION OF APPOINTMENT OF AUDITORS
The Board of Directors, upon the recommendation of the Audit Committee, has
appointed Deloitte & Touche LLP, independent certified public accountants, as
auditors of the Company's financial statements for 2003. Deloitte & Touche LLP
has acted as auditors for the Company since 1990. It is expected that
representatives of Deloitte & Touche LLP will be present at the meeting and will
be available to respond to questions. They will be given an opportunity to make
a statement if they desire to do so.
The Board of Directors has determined to afford stockholders the opportunity to
express their opinions on the matter of auditors, and, accordingly, is
submitting to the stockholders at the Annual Meeting a proposal to ratify the
Board of Directors' appointment of Deloitte & Touche LLP. If a majority of the
shares voted at the Annual Meeting, in person or by proxy, are not voted in
favor of the ratification of the appointment of Deloitte & Touche LLP, the Board
of Directors will interpret this as an instruction to seek other auditors. THE
BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE IN FAVOR OF THE
RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS AUDITORS FOR THE
2003 FISCAL YEAR.
AUDIT FEES -- The Company has been billed a total of approximately $82,980 by
Deloitte & Touche, LLP, the Company's independent auditors, for professional
services rendered in connection with the audit of its consolidated financial
statements for fiscal year 2002, its review of unaudited interim financial
statements included in each of the Company's Forms 10-Q filed during the last
fiscal year and accounting consultations regarding generally accepted accounting
principals.
FINANCIAL INFORMATION SYSTEMS DESIGN AND IMPLEMENTATION FEES -- The Company has
not incurred any fees in connection with financial information systems design
and implementation during fiscal year 2002.
ALL OTHER FEES -- The Company has been billed a total of approximately $24,885
for all other services rendered by Deloitte & Touche that are not set forth
above (which includes services in relation to establishing the Company's German
subsidiary, Kensey Nash Europe GmbH, tax planning, and completing an audit of
the Company's 401(k) Plan).
12
AUDIT COMMITTEE MATTERS
AUDIT COMMITTEE CHARTER -- The Audit Committee has adopted a written charter,
which was attached as Exhibit A to the Company's proxy statement for its 2001
Annual Meeting of Stockholders.
INDEPENDENCE OF AUDIT COMMITTEE MEMBERS -- The Company's Common Stock is listed
on the NASDAQ National Market and the Company is governed by the listing
standards applicable thereto. All members of the Audit Committee of the Board of
Directors have been determined to be "independent directors" pursuant to the
definition contained in Rule 4200(a)(15) of the National Association of
Securities Dealers' Marketplace rules.
AUDIT COMMITTEE REPORT -- In connection with the preparation and filing of the
Company's Annual Report on Form 10-K for fiscal year 2002:
(1) the Audit Committee reviewed and discussed the audited financial
statements with the Company's management and the Company's independent
auditors, including meetings where the Company's management was not
present;
(2) the Audit Committee discussed with the Company's independent auditors
the matters required to be discussed by Statement on Auditing
Standards (SAS) No. 61, Communication with Audit Committees, as
amended by SAS No. 90, Audit Committee Communications;
(3) the Audit Committee discussed with the Company's independent auditors
the results of its audit and examination of the Company's consolidated
financial statements, its evaluation of the Company's internal
controls and its overall assessment of the quality of the Company's
financial accounting and reporting functions;
(4) the Audit Committee received and reviewed the written disclosures and
the letter from the Company's independent auditors required by the
Independence Standards Board Standard No. 1 (Independence Discussions
with Audit Committees) and discussed with the Company's independent
auditors the independent auditor's independence, including any
relationships that may impact their objectivity and independence and
considered the amount of non-audit services and the compatibility of
such non-audit services with the auditor's independence; and
(5) based on the review and discussions referred to above, the Audit
Committee recommended to the Board that the audited financial
statements be included in the 2002 Annual Report on Form 10-K.
AUDIT COMMITTEE
-------------------------------------
C. McCollister Evarts, M.D., Chairman
Walter R. Maupay, Jr.
Steven J. Lee
Robert J. Bobb
13
MISCELLANEOUS AND OTHER MATTERS
SOLICITATION -- The cost of this proxy solicitation will be borne by the
Company. The Company may request banks, brokers, fiduciaries, custodians,
nominees and certain other record holders to send proxies, proxy statements and
other materials to their principals. Such banks, brokers, fiduciaries,
custodians, nominees and other record holders will be reimbursed by the Company
for their reasonable out-of-pocket expenses of solicitation. The Company does
not anticipate that costs and expenses incurred in connection with this proxy
solicitation will exceed an amount normally expended for a proxy solicitation
for an election of directors in the absence of a contest.
PROPOSALS OF STOCKHOLDERS -- Proposals of stockholders for the 2003 Annual
Meeting of Stockholders will not be included in the proxy statement for, or
considered at, that annual meeting unless the proposal is proper for inclusion
in the proxy statement and for consideration and is received by the Secretary of
the Company at the Company's offices between May 9, 2003 and June 8, 2003.
OTHER BUSINESS -- The Board of Directors is not aware of any other matters to be
presented at the Annual Meeting other than those mentioned in the Company's
Notice of Annual Meeting of Stockholders enclosed herewith. If any other matters
are properly brought before the Annual Meeting, however, it is intended that the
persons named in the proxy will vote as the Board of Directors directs.
ADDITIONAL INFORMATION -- THE COMPANY WILL FURNISH WITHOUT CHARGE A COPY OF ITS
AUDIT COMMITTEE CHARTER, AS FILED WITH THE SEC, AND ITS ANNUAL REPORT ON FORM
10-K FOR ITS FISCAL YEAR 2002, AS FILED WITH THE SEC, INCLUDING THE FINANCIAL
STATEMENTS AND ATTACHED SCHEDULES, UPON THE WRITTEN REQUEST OF ANY PERSON WHO IS
A STOCKHOLDER AS OF THE RECORD DATE. THE COMPANY WILL PROVIDE COPIES OF THE
EXHIBITS TO SUCH ANNUAL REPORT UPON PAYMENT OF A REASONABLE FEE, WHICH WILL NOT
EXCEED THE COMPANY'S REASONABLE EXPENSES INCURRED. REQUESTS FOR SUCH MATERIALS
SHOULD BE DIRECTED TO KENSEY NASH CORPORATION--INVESTOR RELATIONS, 55 EAST
UWCHLAN AVENUE, EXTON, PENNSYLVANIA 19341, ATTENTION: SECRETARY.
By order of the Board of Directors,
Joseph W. Kaufmann
President and Secretary
Exton, Pennsylvania
November 6, 2002
14
PROXY KENSEY NASH CORPORATION
Marsh Creek Corporate Center - East Uwchlan Avenue - Exton, Pennsylvania 19341
PROXY FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 4, 2002
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned stockholder(s) hereby appoints Joseph W. Kaufmann and
Douglas G. Evans, and each of them, with full power of substitution, as
attorneys and proxies for and in the name and place of the undersigned, and
hereby authorizes each of them to represent and to vote all of the shares of
Common Stock of Kensey Nash Corporation (the "Company") held of record by the
undersigned as of October 18, 2002 which the undersigned is entitled to vote at
the Annual Meeting of Stockholders to be held on December 4, 2002, at the Top of
the Tower, 1717 Arch Street, 51(st) Floor, Philadelphia Pennsylvania at 10:00
a.m., local time, and any adjournments or postponements thereof.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE FOR ALL NOMINEES
LISTED IN PROPOSAL 1 AND FOR PROPOSAL 2.
1. ELECTION OF DIRECTORS:
<Table>
[ ] FOR all nominees listed below [ ] WITHHOLD AUTHORITY
(except as marked to the contrary below) to vote for all nominees listed below
</Table>
- --------------------------------------------------------------------------------
(Instruction: to withhold authority to vote for any individual nominee, strike a
line through the nominee's name below)
<Table>
Douglas G. Evans, P.E. C. McCollister Evarts, M.D. Walter R. Maupay Jr.
(term to expire in 2005) (term to expire in 2005) (term to expire in 2005)
</Table>
2. PROPOSAL TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE
INDEPENDENT AUDITORS OF THE COMPANY'S FINANCIAL STATEMENTS.
[ ] FOR [ ] AGAINST [ ] ABSTAIN
3. Each of the persons named as proxies herein are authorized, in such person's
discretion, to vote upon such other matters as may properly come before the
Annual Meeting.
(Continued and to be signed and dated on reverse side.)
THIS PROXY, WHEN PROPERLY EXECUTED AND RETURNED IN A TIMELY MANNER, WILL BE
VOTED AT THE ANNUAL MEETING AND ANY ADJOURNMENTS OR POSTPONEMENTS THEREOF IN THE
MANNER DESCRIBED HEREIN. IF NO CONTRARY INDICATION IS MADE THE PROXY WILL BE
VOTED FOR ALL NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSAL 2, AND IN
ACCORDANCE WITH THE JUDGMENT OF THE PERSONS NAMED AS PROXIES HEREIN ON ANY OTHER
MATTERS THAT MAY PROPERLY COME BEFORE THE ANNUAL MEETING.
Dated , 2002
-------------------------------------------
-------------------------------------------
Signature(s)
PLEASE MARK, SIGN, DATE AND RETURN THIS
PROXY CARD PROMPTLY USING THE ENCLOSED
ENVELOPE.
[ ] MARK HERE FOR ADDRESS CHANGE AND NOTE
AT LEFT
This Proxy must be signed exactly as your name appears hereon. When shares are
held by joint tenants, both should sign. Attorneys, executors, administrators,
trustees and guardians should indicate their capacities. If the signer is a
corporation, please print full corporate name and indicate capacity of duly
authorized officer executing on behalf of the corporation. If the signer is a
partnership, please print full partnership name and indicate capacity of duly
authorized person executing on behalf of the partnership.